Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

CFTR potentiators: not an open and shut case.

Clancy JP.

Sci Transl Med. 2014 Jul 23;6(246):246fs27. doi: 10.1126/scitranslmed.3009674.

PMID:
25101884
2.

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.

Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, Randell SH, Boucher RC, Gentzsch M.

Sci Transl Med. 2014 Jul 23;6(246):246ra96. doi: 10.1126/scitranslmed.3008680.

3.

Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.

McPhail GL, Clancy JP.

Drugs Today (Barc). 2013 Apr;49(4):253-60. doi: 10.1358/dot.2013.49.4.1940984.

PMID:
23616952
4.

Pulmonology: CFTR modulators for cystic fibrosis.

Bertoncini E, Colomb-Lippa D.

JAAPA. 2013 Feb;26(2):59-60. No abstract available.

PMID:
23409389
5.

Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

Pettit RS.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26. Review.

PMID:
22739718
6.

F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.

Yang H, Ma T.

Expert Opin Ther Pat. 2015;25(9):991-1002. doi: 10.1517/13543776.2015.1045878. Epub 2015 May 15. Review.

PMID:
25971311
7.

Ivacaftor.

Davis PB, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2012 Apr 30;11(5):349-50. doi: 10.1038/nrd3723. No abstract available.

PMID:
22543461
8.

Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.

Antoniu SA.

Expert Opin Investig Drugs. 2011 Mar;20(3):423-5. doi: 10.1517/13543784.2011.554823. Epub 2011 Feb 9.

PMID:
21303308
9.

Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?

van Koningsbruggen-Rietschel S, Naehrlich L.

Ther Adv Respir Dis. 2015 Aug;9(4):198-200. doi: 10.1177/1753465815579364. No abstract available.

PMID:
26175480
10.

PharmGKB summary: very important pharmacogene information for CFTR.

McDonagh EM, Clancy JP, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Mar;25(3):149-56. doi: 10.1097/FPC.0000000000000112. No abstract available.

11.

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.

O'Reilly R, Elphick HE.

Drug Des Devel Ther. 2013 Aug 30;7:929-37. doi: 10.2147/DDDT.S30345. eCollection 2013. Review.

12.

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.

Kotha K, Clancy JP.

Ther Adv Respir Dis. 2013 Oct;7(5):288-96. doi: 10.1177/1753465813502115. Epub 2013 Sep 3. Review.

PMID:
24004658
13.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.

Clancy JP, Johnson SG, Yee SW, McDonagh EM, Caudle KE, Klein TE, Cannavo M, Giacomini KM; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 Jun;95(6):592-7. doi: 10.1038/clpt.2014.54. Epub 2014 Mar 5.

14.

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.

Sermet-Gaudelus I.

Eur Respir Rev. 2013 Mar 1;22(127):66-71. doi: 10.1183/09059180.00008512. Review.

15.

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Solomon GM, Marshall SG, Ramsey BW, Rowe SM.

Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S3-S13. doi: 10.1002/ppul.23240. Epub 2015 Jun 19. Review.

PMID:
26097168
16.

Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.

Graeber SY, Hug MJ, Sommerburg O, Hirtz S, Hentschel J, Heinzmann A, Dopfer C, Schulz A, Mainz JG, Tümmler B, Mall MA.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE. No abstract available.

PMID:
26568242
17.

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.

Hull J.

J R Soc Med. 2012 Jun;105 Suppl 2:S2-8. doi: 10.1258/jrsm.2012.12s001. Review. No abstract available.

18.

Aquagenic wrinkling of the palms in a patient with cystic fibrosis.

Grasemann H, Ratjen F, Solomon M.

N Engl J Med. 2013 Dec 12;369(24):2362-3. doi: 10.1056/NEJMc1308349. No abstract available.

19.

Cystic fibrosis transmembrane regulator correctors and potentiators.

Rowe SM, Verkman AS.

Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). pii: a009761. doi: 10.1101/cshperspect.a009761. Review.

20.

A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.

Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, Byan-Parker S, Grizzle W, Sorscher EJ, Dransfield MT, Rowe SM.

PLoS One. 2012;7(6):e39809. doi: 10.1371/journal.pone.0039809. Epub 2012 Jun 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk